Gilteritinib, another FLT3 inhibitor approved for the treatment of refractory acute myeloid leukemia, has been associated with retinal hemorrhages, which occurred in 7.72% of patients [145]. The gene discussed is FLT3; the disease is acute myeloid leukemia.